Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.53 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15896220 | 0.89 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAHPGD | |
| SCHEMBL18770762 | 0.88 | FOLH1 (0.63) | FOLH1NAALAD2 | |
| SCHEMBL27098294 | 0.86 | FOLH1 (0.50) | FOLH1POLBKMT2AHPGD | |
| SCHEMBL18782517 | 0.85 | FOLH1 (0.51) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22247625 | 0.82 | FOLH1 (0.62) | FOLH1 | |
| SCHEMBL11977627 | 0.82 | NAALAD2 (0.77) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22228930 | 0.80 | FOLH1 (0.52) | FOLH1NAALAD2 | |
| SCHEMBL22228931 | 0.80 | FOLH1 (0.52) | FOLH1NAALAD2 | |
| SCHEMBL4925425 | 0.80 | ALB (0.50) | FOLH1NAALAD2 | |
| SCHEMBL4925430 | 0.80 | ALB (0.50) | FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
| WO-2017070482-A2 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | PSMA7, PSMA6, PSMA1 | FOLH1 28/4885NAALAD2 547/4885RIMKLA 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.